Nothing Special   »   [go: up one dir, main page]

SG11202110584TA - Monitoring gene therapy - Google Patents

Monitoring gene therapy

Info

Publication number
SG11202110584TA
SG11202110584TA SG11202110584TA SG11202110584TA SG11202110584TA SG 11202110584T A SG11202110584T A SG 11202110584TA SG 11202110584T A SG11202110584T A SG 11202110584TA SG 11202110584T A SG11202110584T A SG 11202110584TA SG 11202110584T A SG11202110584T A SG 11202110584TA
Authority
SG
Singapore
Prior art keywords
gene therapy
monitoring gene
monitoring
therapy
gene
Prior art date
Application number
SG11202110584TA
Inventor
B Nelson Chau
Jing Liao
Susana Gordo
Original Assignee
Logicbio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Logicbio Therapeutics Inc filed Critical Logicbio Therapeutics Inc
Publication of SG11202110584TA publication Critical patent/SG11202110584TA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202110584TA 2019-04-15 2020-04-14 Monitoring gene therapy SG11202110584TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833875P 2019-04-15 2019-04-15
PCT/US2020/028102 WO2020214582A1 (en) 2019-04-15 2020-04-14 Monitoring gene therapy

Publications (1)

Publication Number Publication Date
SG11202110584TA true SG11202110584TA (en) 2021-10-28

Family

ID=72837570

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110584TA SG11202110584TA (en) 2019-04-15 2020-04-14 Monitoring gene therapy

Country Status (13)

Country Link
US (1) US20220308070A1 (en)
EP (1) EP3955972A4 (en)
JP (2) JP2022529433A (en)
KR (1) KR20220021906A (en)
CN (1) CN114072181A (en)
AU (1) AU2020258371A1 (en)
BR (1) BR112021020499A2 (en)
CA (1) CA3135666A1 (en)
IL (1) IL287186A (en)
MA (1) MA55727A (en)
MX (1) MX2021012541A (en)
SG (1) SG11202110584TA (en)
WO (1) WO2020214582A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230098A1 (en) 2022-05-23 2023-11-30 Logicbio Therapeutics, Inc. Gene therapy compositions and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632800B1 (en) * 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
KR20220100728A (en) * 2014-03-21 2022-07-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Genome editing without nucleases
WO2020032986A1 (en) * 2018-08-10 2020-02-13 Logicbio Therapeutics, Inc. Non-disruptive gene therapy for the treatment of mma

Also Published As

Publication number Publication date
EP3955972A4 (en) 2023-01-11
EP3955972A1 (en) 2022-02-23
KR20220021906A (en) 2022-02-22
US20220308070A1 (en) 2022-09-29
JP2024107256A (en) 2024-08-08
CA3135666A1 (en) 2020-10-22
CN114072181A (en) 2022-02-18
MA55727A (en) 2022-02-23
BR112021020499A2 (en) 2021-12-07
AU2020258371A1 (en) 2021-10-28
MX2021012541A (en) 2021-11-12
JP2022529433A (en) 2022-06-22
IL287186A (en) 2021-12-01
WO2020214582A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
CA195571S (en) Stimulator
IL279685A (en) Gene therapy
GB201900702D0 (en) Therapy
SI3612237T1 (en) Gene therapy
GB201905301D0 (en) Gene therapy
IL280165A (en) Glucocerebrosidase gene therapy
ZA202100244B (en) Combinatorial gene therapy
GB201707212D0 (en) Gene therapy for ciliopathies
GB201912191D0 (en) New therapy
IL287186A (en) Monitoring gene therapy
GB201817470D0 (en) Gene therapy
GB201802326D0 (en) Gene therapy
GB201701968D0 (en) Gene therapy
GB201918752D0 (en) New therapy
EP3760209C0 (en) Ischemic-lesion-site-specific gene therapy
GB201906864D0 (en) Combination therapy
GB201818579D0 (en) New therapy
GB201814036D0 (en) New therapy
GB201820982D0 (en) Gene Therapy
GB201811541D0 (en) Gene therapy
IL277696A (en) Gene therapy for oxidative stress
GB201801511D0 (en) Gene therapy
GB201919036D0 (en) Therapy
GB201916983D0 (en) Therapy
GB201914848D0 (en) Therapy